24.30SEK0.00%Mkt Cap: 1.17B SEKP/E: —Last update: 2026-05-13
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-15.53
PEG—
P/B1.71
P/S474.93
EV/EBITDA-7.16
EV/Revenue429.10
EPS (TTM)-4.10
EPS (Forward)-1.59
Cash Flow & Leverage
FCF Yield-10.08%
FCF Margin-4788.44%
Operating CF-193.16M SEK
CapEx (TTM)29.19M SEK
Net Debt/EBITDA-0.18
Net Debt27.13M SEK
Technical
SMA 5026.32 (-7.7%)
SMA 20032.21 (-24.6%)
Beta-0.06
S&P 52W Chg24.23%
Avg Vol (30d)90.66K
Avg Vol (10d)160.71K
Technical Indicators
RSI (14)41.2
MACD-0.7995
MACD Signal-0.5027
MACD Hist.-0.2968
BB Upper29.90 SEK
BB Middle26.25 SEK
BB Lower22.61 SEK
BB Width27.75%
ATR (14)1.562 SEK
Vol Ratio (20d)0.91x
52W Range
22.464% of range64.10
52W High64.10 SEK
52W Low22.46 SEK
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin-6095.46%
ROE-28.35%
ROA-22.28%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity0.25
Current Ratio1.02
Quick Ratio0.84
Book Value/Sh14.48 SEK
Cash/Share2.892 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.47.42M
Float29.86M
Insiders28.34%
Institutions41.87%
Analyst Consensus
Rating—
Target (Mean)60.00 SEK
Target Range60.00 SEK – 60.00 SEK
# Analysts1
Company
Market Cap1.17B SEK
Enterprise Value1.06B SEK
Revenue (TTM)2.47M SEK
Gross Profit2.47M SEK
Net Income (TTM)-171.44M SEK
Revenue/Share0.0620 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees24
Last Price24.30 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—